STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

MYGN 8-K: Natalie Munk to resign; CFO Wheeler to assume accounting officer role

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Myriad Genetics reported that Natalie Munk, its Senior Vice President and Chief Accounting Officer, notified the company on September 29, 2025 that she will resign effective October 24, 2025. The filing states her departure is not the result of any disagreement with the company on operations, policies or practices. To maintain accounting leadership, the Board designated Benjamin R. Wheeler, the company’s Chief Financial Officer since August 2025, to serve additionally as principal accounting officer upon Ms. Munk’s departure. The filing notes Mr. Wheeler has worked at Myriad for over a decade, is a CPA, holds accounting degrees from Brigham Young University, and received no additional compensation for the designation.

Positive

  • Internal succession via long-tenured executive with 13 years at the company
  • No disagreement with the company cited concerning the departing accounting officer
  • No additional compensation granted to the CFO for taking the principal accounting officer role

Negative

  • Departure of the company’s principal accounting officer effective October 24, 2025
  • Consolidation of CFO and principal accounting officer duties may increase operational risk absent disclosed support or controls

Insights

TL;DR: Leadership change ensures internal continuity with no disclosed disputes.

The company disclosed the resignation of its principal accounting officer effective October 24, 2025 while explicitly stating there was no disagreement with management, which reduces immediate governance concern.

Board action to designate Benjamin R. Wheeler—the existing CFO since August 2025—to also serve as principal accounting officer signals operational continuity because he has held multiple finance and accounting roles at Myriad over the past thirteen years.

TL;DR: Consolidating CFO and principal accounting officer roles raises oversight and workload considerations.

Assigning the principal accounting officer role to the current CFO means the same executive will carry responsibility for both financial strategy and accounting controls; the filing states no additional compensation was granted for this role change.

This is factual disclosure only; the filing contains no mention of changes to internal control evaluations, finance staffing, or transitional plans.

0000899923false00008999232025-09-292025-09-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  September 29, 2025
 
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware 0-26642 87-0494517
(State or other jurisdiction of
incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
 
322 North 2200 West
Salt Lake City, Utah 84116
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, $0.01 par value MYGN Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Natalie Munk as Principal Accounting Officer

On September 29, 2025, Natalie Munk, the Senior Vice President, Chief Accounting Officer and principal accounting officer of Myriad Genetics, Inc.’s (the “Company”), provided notice of her resignation from the Company, effective on October 24, 2025. Ms. Munk’s departure is not a result of any disagreement between Ms. Munk and the Company on any matter relating to the Company’s operations, policies or practices.

Appointment of Ben R. Wheeler as as Principal Accounting Officer

In connection with Ms. Munk’s departure, on October 1, 2025, the Board of Directors of the Company (the “Board”) designated Benjamin R. Wheeler, the Company’s Chief Financial Officer and principal financial officer, to also serve as the Company’s principal accounting officer, effective upon Ms. Munk’s departure from the Company.

Mr. Wheeler, 42, has served as the Company’s Chief Financial Officer since August 2025. Prior to that, Mr. Wheeler served in various roles of increasing responsibility at the Company over the past thirteen years, including Senior Vice President, Chief Financial Officer, Operations, since June 2022, and Senior Vice President, Finance and Treasury, since July 2020. Mr. Wheeler has also served at the Company as Senior Vice President, Accounting, from June 2018 to July 2020, Vice President, Corporate Controller, from December 2014 to June 2018, and in other controllership positions from December 2011 to December 2014. Before joining the Company, Mr. Wheeler served as an auditor for Ernst & Young. Mr. Wheeler holds both master’s and bachelor’s degrees in accounting from Brigham Young University and is a Certified Public Accountant.

Mr. Wheeler did not receive any additional compensation upon his designation as principal accounting officer of the Company. There are no arrangements or understandings between Mr. Wheeler and any other person pursuant to which he was designated as the Company's principal accounting officer. Additionally, Mr. Wheeler is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K, and he does not have any family relationships that are required to be disclosed pursuant to Item 401(d) of Regulation S-K.



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
MYRIAD GENETICS, INC.
Date: October 3, 2025By:/s/ Benjamin R. Wheeler
Benjamin R. Wheeler
Chief Financial Officer



FAQ

What did Myriad Genetics (MYGN) disclose in the 8-K about its principal accounting officer?

Myriad disclosed that Natalie Munk will resign effective October 24, 2025 and that Benjamin R. Wheeler will be designated as the company’s principal accounting officer upon her departure.

Does the filing state there was a disagreement leading to the resignation?

No. The filing explicitly states Ms. Munk’s departure is not the result of any disagreement with the company on operations, policies, or practices.

Will Benjamin R. Wheeler receive additional pay for the principal accounting officer role?

The filing states Mr. Wheeler did not receive any additional compensation upon his designation as principal accounting officer.

What are Benjamin R. Wheeler’s qualifications per the filing?

Mr. Wheeler has served as CFO since August 2025, has held multiple finance and accounting roles at Myriad over the past thirteen years, is a CPA, and holds bachelor’s and master’s degrees in accounting from Brigham Young University.

Was any related-party transaction or family relationship disclosed for Mr. Wheeler?

No. The filing states Mr. Wheeler is not a party to any transaction requiring disclosure under Item 404(a) of Regulation S-K and has no family relationships required to be disclosed under Item 401(d).
Myriad Genetics

NASDAQ:MYGN

MYGN Rankings

MYGN Latest News

MYGN Latest SEC Filings

MYGN Stock Data

680.46M
90.13M
2.9%
98.4%
9.66%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
SALT LAKE CITY